Pipeline

Program

Indication

AI Discovery

Preclinical

IND enabling

Phase 1

Phase 2

Pivotal (2b/3)

HLX-1502

Neurofibromatosis Type 1

HLX-0213

Neurofibromatosis Type 1

Undisclosed

Rare and Pediatric Oncology

Rare Neurology

HLX-0206

Fragile X Syndrome

HLX-0553

Angelman Syndrome

Undisclosed

Rare Renal

HLX-2607

Autosomal Dominant Polycystic Kidney Disease

Meet some of our team

Dr Mark Youssef

Global Head of Business Development and Licensing

(Pharmaceutical & biotech groups)

Dr Bruce Bloom

Chief Collaboration Officer

(Patient & academic groups)